SK Chemicals’ hemophilia therapy ‘AFSTYLA’ approved in Canada

Published: 2016-12-20 10:40:51

Updated: 2016-12-20 10:40:51

SK Chemicals(CEO Man-Hoon Park) announced on the 18^th that its hemophilia treatment ‘AFSTYLA’ acquired commercialization approval from the Canadian health authorities Health Canada after the one from the U.S. FDA.

CSL Ltd. have gone through the manufacturing process development, global clinical trials and approval application for AFSTYLA, a biomedicine developed by SK Chemicals and licensed ou...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.